TargetAcquirerPrice
Pharmaceuticals
R-Pharm US LLCIxempra®N/A
AbbVie Inc.Rights to a Priority Review Voucher$350 million
Valeant Pharmaceuticals InternationalSprout Pharmaceuticals, Inc.$1 billion
Raptor Pharmaceuticals Corp.Quinsair™$68.4 million
Novartis AGRemaining rights to ofatumumab$300 million